File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Effects of pharmacological agents for neurogenic oropharyngeal dysphagia: A systematic review and meta-analysis

TitleEffects of pharmacological agents for neurogenic oropharyngeal dysphagia: A systematic review and meta-analysis
Authors
Keywordsdrugs
dysphagia
meta-analysis
pharmacotherapy
systematic review
treatment
Issue Date2022
Citation
Neurogastroenterology and Motility, 2022, v. 34, n. 3, article no. e14220 How to Cite?
AbstractBackground: This systematic review and meta-analysis aimed to evaluate the effects of pharmacological agents for neurogenic oropharyngeal dysphagia based on evidence from randomized controlled trials (RCTs). Methods: Electronic databases were systematically searched between January 1970 and March 2021. Two reviewers independently extracted and synthesized the data. The outcome measure was changed in (any) relevant clinical swallowing-related characteristics. Key results: Data from 2186 dysphagic patients were collected from 14 RCT studies across a range of pharmacotherapies. The pooled effect size of transient receptor potential (TRP) channel agonists was large compared to placebo interventions (SMD[95%CI] =1.27[0.74,1.80], p < 0.001; I2 = 79%). Data were limited for other pharmacological agents and the overall pooled effect size of these agents was non-significant (SMD [95% CI] =0.25 [−0.24, 0.73]; p = 0.31; I2 = 85%). When analyzed separately, large effect sizes were observed with Nifedipine (SMD[95%CI] =1.13[0.09,2.18]; p = 0.03) and Metoclopramide (SMD[95%CI] =1.68[1.08,2.27]; p < 0.001). By contrast, the effects of angiotensin-converting enzyme (ACE) inhibitors (SMD[95%CI] = −0.67[−2.32,0.99]; p = 0.43; I2 = 61%), Physostigmine (SMD[95%CI] = −0.05[−1.03,0.93]; p = 0.92) and Glyceryl Trinitrate (GTN) (SMD [95% CI] = −0.01 [−0.11, 0.08]; p = 0.78) were non-significant. Within stroke patients, subgroup analysis showed that TRP channel agonists had a moderate pooled effect size (SMD[95%CI] =0.74[0.10,1.39]; p = 0.02; I2 = 82%) whereas the effects of other agents were non-significant (SMD[95%CI] =0.40[−0.04,0.84]; p = 0.07; I2 = 87%). Conclusions & Inferences: Our results showed that TRP channel agonists, Nifedipine and Metoclopromide may be beneficial for neurogenic dysphagic patients. Large scale, multicenter clinical trials are warranted to fully explore their therapeutic effects on swallowing.
Persistent Identifierhttp://hdl.handle.net/10722/334773
ISSN
2023 Impact Factor: 3.5
2023 SCImago Journal Rankings: 1.312
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorCheng, Ivy-
dc.contributor.authorSasegbon, Ayodele-
dc.contributor.authorHamdy, Shaheen-
dc.date.accessioned2023-10-20T06:50:38Z-
dc.date.available2023-10-20T06:50:38Z-
dc.date.issued2022-
dc.identifier.citationNeurogastroenterology and Motility, 2022, v. 34, n. 3, article no. e14220-
dc.identifier.issn1350-1925-
dc.identifier.urihttp://hdl.handle.net/10722/334773-
dc.description.abstractBackground: This systematic review and meta-analysis aimed to evaluate the effects of pharmacological agents for neurogenic oropharyngeal dysphagia based on evidence from randomized controlled trials (RCTs). Methods: Electronic databases were systematically searched between January 1970 and March 2021. Two reviewers independently extracted and synthesized the data. The outcome measure was changed in (any) relevant clinical swallowing-related characteristics. Key results: Data from 2186 dysphagic patients were collected from 14 RCT studies across a range of pharmacotherapies. The pooled effect size of transient receptor potential (TRP) channel agonists was large compared to placebo interventions (SMD[95%CI] =1.27[0.74,1.80], p < 0.001; I2 = 79%). Data were limited for other pharmacological agents and the overall pooled effect size of these agents was non-significant (SMD [95% CI] =0.25 [−0.24, 0.73]; p = 0.31; I2 = 85%). When analyzed separately, large effect sizes were observed with Nifedipine (SMD[95%CI] =1.13[0.09,2.18]; p = 0.03) and Metoclopramide (SMD[95%CI] =1.68[1.08,2.27]; p < 0.001). By contrast, the effects of angiotensin-converting enzyme (ACE) inhibitors (SMD[95%CI] = −0.67[−2.32,0.99]; p = 0.43; I2 = 61%), Physostigmine (SMD[95%CI] = −0.05[−1.03,0.93]; p = 0.92) and Glyceryl Trinitrate (GTN) (SMD [95% CI] = −0.01 [−0.11, 0.08]; p = 0.78) were non-significant. Within stroke patients, subgroup analysis showed that TRP channel agonists had a moderate pooled effect size (SMD[95%CI] =0.74[0.10,1.39]; p = 0.02; I2 = 82%) whereas the effects of other agents were non-significant (SMD[95%CI] =0.40[−0.04,0.84]; p = 0.07; I2 = 87%). Conclusions & Inferences: Our results showed that TRP channel agonists, Nifedipine and Metoclopromide may be beneficial for neurogenic dysphagic patients. Large scale, multicenter clinical trials are warranted to fully explore their therapeutic effects on swallowing.-
dc.languageeng-
dc.relation.ispartofNeurogastroenterology and Motility-
dc.subjectdrugs-
dc.subjectdysphagia-
dc.subjectmeta-analysis-
dc.subjectpharmacotherapy-
dc.subjectsystematic review-
dc.subjecttreatment-
dc.titleEffects of pharmacological agents for neurogenic oropharyngeal dysphagia: A systematic review and meta-analysis-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/nmo.14220-
dc.identifier.pmid34337829-
dc.identifier.scopuseid_2-s2.0-85111697508-
dc.identifier.volume34-
dc.identifier.issue3-
dc.identifier.spagearticle no. e14220-
dc.identifier.epagearticle no. e14220-
dc.identifier.eissn1365-2982-
dc.identifier.isiWOS:000760394800015-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats